Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 1997

View Archived Issues

Immune Response's TCR vaccine evaluated in MS patients

Parke-Davis initiates QUASAR trial of quinapril

Dovetail issued patent for Betathine

Pacific Pharmaceuticals and Steri-Oss sign distribution agreement

Familial Mediterranean fever gene discovered

Neurochemical actions of ARL-12495AA, the active metabolite of remacemide

Antiarrhythmic effects of 5-HT2 antagonist/TxA2 antagonist combination investigated

BMS reports new cephalosporins active against MRSA

Tasmar approved in EU for Parkinson's disease

Gensia's injectable diltiazem receives ANDA approval

Roche withdraws NDA for orlistat

FDA approves Hi-Tech's generic promethazine/codeine syrup

Marketing agreement reached for Abelcet in France and Italy

Eurand and Global enter pancrelipase agreement

Canadian marketing clearance granted for Emdogain

Morphine derivatives discovered by Nycomed

FDA approves nonsurgical treatment for BPH

ImmunoGen's apoptosis research receives patent protection

Alza will acquire Therapeutic Discovery Corporation

Val-HeFT will evaluate valsartan in CHF

New Parkinson's disease treatment option now available in Canada

New indication approved for Asacol

First regulatory submission filed for Macritonin

CURVES study results point in favor of atorvastatin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...